vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Zedge, Inc. (ZDGE). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.6M, roughly 1.2× Zedge, Inc.). Zedge, Inc. runs the higher net margin — 10.4% vs -60.3%, a 70.7% gap on every dollar of revenue. On growth, Zedge, Inc. posted the faster year-over-year revenue change (5.8% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $808.0K). Over the past eight quarters, Zedge, Inc.'s revenue compounded faster (-1.0% CAGR vs -6.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Zedge is a content distribution platform that provides consumers with a way to personalize their mobile devices. It has offices in Trondheim, Vilnius, and New York City.
PLX vs ZDGE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $7.6M |
| Net Profit | $-5.5M | $788.0K |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | 12.0% |
| Net Margin | -60.3% | 10.4% |
| Revenue YoY | -49.9% | 5.8% |
| Net Profit YoY | -184.8% | 332.4% |
| EPS (diluted) | $-0.06 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $7.6M | ||
| Q3 25 | $17.9M | $7.5M | ||
| Q2 25 | $15.7M | $7.8M | ||
| Q1 25 | $10.1M | $7.0M | ||
| Q4 24 | $18.2M | $7.2M | ||
| Q3 24 | $18.0M | $7.6M | ||
| Q2 24 | $13.5M | $7.7M | ||
| Q1 24 | — | $7.8M |
| Q4 25 | $-5.5M | $788.0K | ||
| Q3 25 | $2.4M | $-559.0K | ||
| Q2 25 | $164.0K | $185.0K | ||
| Q1 25 | $-3.6M | $-1.7M | ||
| Q4 24 | $6.5M | $-339.0K | ||
| Q3 24 | $3.2M | $-39.0K | ||
| Q2 24 | $-2.2M | $113.0K | ||
| Q1 24 | — | $-9.2M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | 12.0% | ||
| Q3 25 | 11.9% | -9.6% | ||
| Q2 25 | 7.5% | 2.1% | ||
| Q1 25 | -41.0% | -31.8% | ||
| Q4 24 | 39.6% | -6.4% | ||
| Q3 24 | 22.2% | -0.8% | ||
| Q2 24 | -18.0% | -1.7% | ||
| Q1 24 | — | -153.5% |
| Q4 25 | -60.3% | 10.4% | ||
| Q3 25 | 13.2% | -7.5% | ||
| Q2 25 | 1.0% | 2.4% | ||
| Q1 25 | -35.8% | -24.1% | ||
| Q4 24 | 35.6% | -4.7% | ||
| Q3 24 | 18.0% | -0.5% | ||
| Q2 24 | -16.4% | 1.5% | ||
| Q1 24 | — | -118.8% |
| Q4 25 | $-0.06 | $0.06 | ||
| Q3 25 | $0.03 | $-0.04 | ||
| Q2 25 | $0.00 | $0.01 | ||
| Q1 25 | $-0.05 | $-0.12 | ||
| Q4 24 | $0.10 | $-0.02 | ||
| Q3 24 | $0.03 | $0.00 | ||
| Q2 24 | $-0.03 | $0.01 | ||
| Q1 24 | — | $-0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $18.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $25.9M |
| Total Assets | $82.3M | $36.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $18.5M | ||
| Q3 25 | $13.6M | $18.6M | ||
| Q2 25 | $17.9M | $20.4M | ||
| Q1 25 | $19.5M | $20.1M | ||
| Q4 24 | $19.8M | $20.2M | ||
| Q3 24 | $27.4M | $20.0M | ||
| Q2 24 | $23.4M | $19.9M | ||
| Q1 24 | — | $18.1M |
| Q4 25 | $48.2M | $25.9M | ||
| Q3 25 | $52.9M | $25.9M | ||
| Q2 25 | $49.9M | $28.6M | ||
| Q1 25 | $45.2M | $28.2M | ||
| Q4 24 | $43.2M | $30.1M | ||
| Q3 24 | $32.4M | $30.9M | ||
| Q2 24 | $28.6M | $30.9M | ||
| Q1 24 | — | $30.7M |
| Q4 25 | $82.3M | $36.0M | ||
| Q3 25 | $82.3M | $35.7M | ||
| Q2 25 | $78.5M | $37.8M | ||
| Q1 25 | $73.9M | $37.1M | ||
| Q4 24 | $73.4M | $38.2M | ||
| Q3 24 | $61.6M | $38.2M | ||
| Q2 24 | $91.5M | $38.1M | ||
| Q1 24 | — | $37.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $825.0K |
| Free Cash FlowOCF − Capex | $1.6M | $808.0K |
| FCF MarginFCF / Revenue | 17.8% | 10.6% |
| Capex IntensityCapex / Revenue | 4.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.05× |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $3.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $825.0K | ||
| Q3 25 | $-3.7M | $674.0K | ||
| Q2 25 | $-5.2M | $870.0K | ||
| Q1 25 | $-5.1M | $708.0K | ||
| Q4 24 | $4.0M | $1.2M | ||
| Q3 24 | $4.1M | $695.0K | ||
| Q2 24 | $-3.6M | $2.3M | ||
| Q1 24 | — | $1.6M |
| Q4 25 | $1.6M | $808.0K | ||
| Q3 25 | $-4.2M | $640.0K | ||
| Q2 25 | $-5.7M | $851.0K | ||
| Q1 25 | $-5.4M | $689.0K | ||
| Q4 24 | $3.6M | $1.2M | ||
| Q3 24 | $4.0M | $683.0K | ||
| Q2 24 | $-3.8M | $2.3M | ||
| Q1 24 | — | $1.6M |
| Q4 25 | 17.8% | 10.6% | ||
| Q3 25 | -23.7% | 8.6% | ||
| Q2 25 | -36.2% | 11.0% | ||
| Q1 25 | -53.0% | 9.9% | ||
| Q4 24 | 19.6% | 16.1% | ||
| Q3 24 | 22.4% | 9.0% | ||
| Q2 24 | -28.1% | 30.4% | ||
| Q1 24 | — | 20.0% |
| Q4 25 | 4.4% | 0.2% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 2.8% | 0.2% | ||
| Q1 25 | 3.0% | 0.3% | ||
| Q4 24 | 2.3% | 0.2% | ||
| Q3 24 | 0.5% | 0.2% | ||
| Q2 24 | 1.3% | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | 1.05× | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | 4.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | 20.73× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
ZDGE
| Zedge Marketplace | $7.1M | 94% |
| Other | $468.0K | 6% |
